RESULTS
Respondents, stratified by professional healthcare titles, number of years in practice, care center type, and U.S. regions, were asked how the release of the NYT article influenced their dermatology practice. A specific focus was placed on whether they had appreciated an increase in patient visits to discuss and/or prescribe LDOM, and if they ultimately found themselves prescribing it at a greater frequency than prior to the NYT article (Table 1). 71% of surveyed respondents reported a surge in LDOM inquiry, with Board Certified Dermatologists (68.4%) and Dermatology Residents (62.5%) seeing the greatest spikes, irrespective of their number of years in practice. 76.9% of the 13 respondents working in Community Hospitals/ Multispecialty Clinics reported increases in LDOM interest, followed by Private Practices (48, n= 71) and Academic Institutions/VA (20, n= 31) closely tying the list at 67.6% and 64.5%, respectively. 83.5% reported seeing 0-to-5 and 13.4% 5-to-10 new patients per week, combined with 75.3% seeing 0-to-5 and 22.7% 5-to-10 returning patients per week with the above medication request. Most notably, a total of 85.6% of respondents accounting for all U.S. demographic regions reported significant increases in LDOM prescriptions.
